Characteristics of HIV-1—infected patients
Patient . | Sex . | Age, y . | HIV-1+ year . | CD4+, % . | CD4+ cells, μL-1 . | CD8+, % . | CD8+ cells, μL-1 . | CD4/CD8 ratio . | Therapy . | Stage* . | HIV RNA, copies/mL-1 . |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 32 | 2001 | 36 | 450 | 27 | 340 | 1.3 | No | A | < 80 |
2 | F | 31 | 2002 | 24 | 327 | 43 | 473 | 0.7 | No | A | 27 000 |
3 | F | 38 | 1988 | 43 | 1159 | 40 | 1080 | 0.9 | No | A | 9000 |
4 | F | 55 | 1997 | 41 | 510 | 39 | 487 | 1.0 | No | A | 8100 |
5 | M | 42 | 2000 | 22 | 582 | 43 | 1075 | 0.5 | No | A | 17 000 |
6 | F | 55 | 2003 | 40 | 783 | 40 | 788 | 1.0 | No | A | 6800 |
7 | F | 43 | 1987 | 26 | 378 | 62 | 909 | 0.4 | No | A | < 80 |
8 | F | 36 | 1994 | 10 | 55 | 54 | 313 | 0.2 | No | A | 24 000 |
9 | F | 69 | 1996 | 15 | 449 | 45 | 1402 | 0.3 | D4T, DDI, EFV | B | < 80 |
10 | M | 67 | 1996 | 49 | 981 | 26 | 525 | 1.9 | D4T, 3TC, EFV | A | < 80 |
11 | M | 38 | 2001 | 24 | 469 | 42 | 1178 | 0.4 | D4T, DDI, EFV | A | < 80 |
12 | M | 62 | 2001 | 34 | 698 | 40 | 800 | 0.9 | AZT, 3TC, ABC | A | < 80 |
13 | M | 37 | 2000 | 32 | 662 | 36 | 740 | 0.9 | AZT, 3TC, ABC | A | < 80 |
14 | M | 33 | 2001 | 38 | 736 | 36 | 696 | 1.0 | AZT, 3TC, ABC | A | < 80 |
15 | M | 73 | 2001 | 31 | 727 | 42 | 966 | 0.7 | AZT, 3TC, EFV | A | < 80 |
16 | M | 45 | 2002 | 26 | 294 | 41 | 451 | 0.6 | D4T, DDI, EFV | A | < 80 |
17 | M | 46 | 1988 | 29 | 698 | 51 | 1224 | 0.6 | EFU, 3TC, LPN | A | < 80 |
18 | F | 59 | 1996 | 13 | 182 | 42 | 588 | 0.3 | D4T, DDI, EFV | C | < 80 |
19 | M | 43 | 2000 | 36 | 524 | 31 | 451 | 1.1 | D4T, DDI, EFV | C | < 80 |
20 | M | 27 | 2001 | 50 | 1311 | 32 | 836 | 1.6 | AZT, 3TC, ABC | A | < 80 |
21 | F | 43 | 2000 | 39 | 667 | 40 | 676 | 0.6 | AZT, 3TC, EFV | A | < 80 |
22 | M | 37 | 1985 | 40 | 899 | 36 | 816 | 1.1 | D4T, DDI, EFV | A | < 80 |
23 | M | 41 | 1985 | 38 | 452 | 28 | 339 | 1.3 | AZT, 3TC, DDI | A | < 80 |
24 | M | 30 | 2000 | 27 | 686 | 16 | 405 | 1.7 | AZT, 3TC, EFV | C | < 80 |
25 | F | 34 | 1994 | 47 | 920 | 12 | 235 | 3.9 | D4T, DDI, EFV | A | < 80 |
26 | F | 35 | 2000 | 40 | 1295 | 33 | 1076 | 1.2 | AZT, 3TC, EFV | A | < 80 |
27 | F | 31 | 1996 | 44 | 921 | 39 | 822 | 1.1 | NVL, SQN-sg | A | < 80 |
28 | F | 56 | 2003 | 2 | 8 | 43 | 172 | 0 | AZT, 3TC, LPN, R | A | 5000 |
Patient . | Sex . | Age, y . | HIV-1+ year . | CD4+, % . | CD4+ cells, μL-1 . | CD8+, % . | CD8+ cells, μL-1 . | CD4/CD8 ratio . | Therapy . | Stage* . | HIV RNA, copies/mL-1 . |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 32 | 2001 | 36 | 450 | 27 | 340 | 1.3 | No | A | < 80 |
2 | F | 31 | 2002 | 24 | 327 | 43 | 473 | 0.7 | No | A | 27 000 |
3 | F | 38 | 1988 | 43 | 1159 | 40 | 1080 | 0.9 | No | A | 9000 |
4 | F | 55 | 1997 | 41 | 510 | 39 | 487 | 1.0 | No | A | 8100 |
5 | M | 42 | 2000 | 22 | 582 | 43 | 1075 | 0.5 | No | A | 17 000 |
6 | F | 55 | 2003 | 40 | 783 | 40 | 788 | 1.0 | No | A | 6800 |
7 | F | 43 | 1987 | 26 | 378 | 62 | 909 | 0.4 | No | A | < 80 |
8 | F | 36 | 1994 | 10 | 55 | 54 | 313 | 0.2 | No | A | 24 000 |
9 | F | 69 | 1996 | 15 | 449 | 45 | 1402 | 0.3 | D4T, DDI, EFV | B | < 80 |
10 | M | 67 | 1996 | 49 | 981 | 26 | 525 | 1.9 | D4T, 3TC, EFV | A | < 80 |
11 | M | 38 | 2001 | 24 | 469 | 42 | 1178 | 0.4 | D4T, DDI, EFV | A | < 80 |
12 | M | 62 | 2001 | 34 | 698 | 40 | 800 | 0.9 | AZT, 3TC, ABC | A | < 80 |
13 | M | 37 | 2000 | 32 | 662 | 36 | 740 | 0.9 | AZT, 3TC, ABC | A | < 80 |
14 | M | 33 | 2001 | 38 | 736 | 36 | 696 | 1.0 | AZT, 3TC, ABC | A | < 80 |
15 | M | 73 | 2001 | 31 | 727 | 42 | 966 | 0.7 | AZT, 3TC, EFV | A | < 80 |
16 | M | 45 | 2002 | 26 | 294 | 41 | 451 | 0.6 | D4T, DDI, EFV | A | < 80 |
17 | M | 46 | 1988 | 29 | 698 | 51 | 1224 | 0.6 | EFU, 3TC, LPN | A | < 80 |
18 | F | 59 | 1996 | 13 | 182 | 42 | 588 | 0.3 | D4T, DDI, EFV | C | < 80 |
19 | M | 43 | 2000 | 36 | 524 | 31 | 451 | 1.1 | D4T, DDI, EFV | C | < 80 |
20 | M | 27 | 2001 | 50 | 1311 | 32 | 836 | 1.6 | AZT, 3TC, ABC | A | < 80 |
21 | F | 43 | 2000 | 39 | 667 | 40 | 676 | 0.6 | AZT, 3TC, EFV | A | < 80 |
22 | M | 37 | 1985 | 40 | 899 | 36 | 816 | 1.1 | D4T, DDI, EFV | A | < 80 |
23 | M | 41 | 1985 | 38 | 452 | 28 | 339 | 1.3 | AZT, 3TC, DDI | A | < 80 |
24 | M | 30 | 2000 | 27 | 686 | 16 | 405 | 1.7 | AZT, 3TC, EFV | C | < 80 |
25 | F | 34 | 1994 | 47 | 920 | 12 | 235 | 3.9 | D4T, DDI, EFV | A | < 80 |
26 | F | 35 | 2000 | 40 | 1295 | 33 | 1076 | 1.2 | AZT, 3TC, EFV | A | < 80 |
27 | F | 31 | 1996 | 44 | 921 | 39 | 822 | 1.1 | NVL, SQN-sg | A | < 80 |
28 | F | 56 | 2003 | 2 | 8 | 43 | 172 | 0 | AZT, 3TC, LPN, R | A | 5000 |
HIV-1+ year was year of seroconversion.
D4T indicates stavudine; DDI, didanosine; EFV, efavirenz; 3TC, lamivudine; AZT, zidovudine; ABC, abaqavir; NVL, nelfinavir; SQN-sg, saquinavir soft gel; LPN, lopinavir; and R, ritonavir.
Stage was defined according to CDC criteria.